|
The Union ministry of health and family welfare has notified the inclusion of the drug pregabalin under Schedule H1 of the Drugs Rules, 1945 in view of reports received from certain states regarding the misuse and abuse of the drug, particularly among youth.
The Ministry issued the notification on May 13, 2026, and published in the Gazette of India Extraordinary on May 20, 2026.
The drug, which is prescribed for the treatment of chronic pain, neuropathies, fibromyalgia, and certain neurological conditions, has reportedly been misused for its sedative, euphoric, and dissociative effects. Seizures of pregabalin illegally stocked and sold without authorisation have also been reported from some parts of the country recently.
With this notification, pregabalin will now be regulated under the stricter provisions of Schedule H1, instead of the existing Schedule H, under the Drugs and Cosmetics Rules, 1945.
This include warning that it is dangerous to take this preparation except in accordance with the medical advice, and that it is not to be sold by retail without the prescription of a Registered Medical Practitioner.
The revised classification mandates that the drug can be sold only against a valid prescription issued by a Registered Medical Practitioner (RMP), and the retailers must maintain a separate register recording details of prescriptions and sales;
Manufacturers shall prominently display the prescribed “Schedule H1 Drug Warning” label on product packaging.
"Violations and non-compliance will attract penal action under the Drugs and Cosmetics Act, 1940 and Rules thereunder," said the Ministry.
The measure is aimed at strengthening accountability across the supply chain, preventing unauthorised access, enhancing prescription monitoring, curbing illegal trafficking, and safeguarding public health from drug misuse and abuse, it added.
The Ministry also sought all stakeholders, including manufacturers, distributors, wholesalers, retailers, and pharmacists, are advised to ensure strict compliance with the provisions of the notification.
As reported earlier, the move to include the drug under Schedule H1 follows the recommendation of the Drugs Technical Advisory Board in its 65th meeting held on December 20, 2024. The Drugs Consultative Committee (DCC) has earlier considered the issue of potential misuse of the drug, along with opioid pain-relief medicine tapentadol and appointed a sub-committee to look into the issue.
During the period from January to December, 2024, the Food & Drugs Administration (Drugs Wing), Government of Punjab, seized drug formulations containing pregabalin from 72 premises or firms, amounting to Rs. 5.97 crore. Additionally, the licenses of 12 firms were cancelled, licenses of 46 firms had been suspended and 11 complaints have been filed in the courts.
The drug regulatory authority from Punjab informed the DCC that the drugs formulations containing pregabalin 150mg/300mg are being misused for intoxication, and requested that the pregabalin and its preparations may be included in Schedule H1 of the Drugs Rules 1945.
Further, as the said drugs do not have much therapeutic usage and are being misused for intoxication, continuation of DCGI approvals of the dosage forms containing pregabalin 150 mg and 300 mg may be re-evaluated, it added.
|